On the other hand, several studies suggest that overexpression of the wild-type of ARID1A in patients with melanoma is more responsive to immune checkpoint inhibitors, while patients with loss of ARID1A may have therapeutic implications by modulating response to immunotherapy (21–23). This evidence concerns the gene ARID1A and melanoma.